Table of contents

Clinical/translational cancer immunotherapy

• Original research: First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors (31 October, 2023)

  Rom Leidner, Kevin Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A O’Keeffe, Nancy Lewis, George N Pavlakis, John A Thompson
• Original research: PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma (25 October, 2023)

  Krisztian Homicsko, Panagiota Zygoura, Maxim Norkin, Stephanie Tissot, Nicholas Shakarishvili, Sanjay Popat, Alessandra Curioni-Fontecedro, Mary O'Brien, Anthony Pope, Riyaz Shah, Patricia Fisher, James Spicer, Amy Roy, David Gilligan, Sylvie Rusakiewicz, Ekaterina Fortis, Nesa Marti, Roswitha Kammler, Stephen P Finn, Georges Coukos, Urania Dafni, Solange Peters, Rolf A Stahel
• Original research: Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D (21 October, 2023)

  Junsik Park, Jung Bok Lee, Myong Cheol Lim, Byoung-Gie Kim, Jae-Weon Kim, Sunghoon Kim, Chel Hun Choi, Hee Seung Kim, Sang Yoon Park, Jung-Yun Lee
• Original research: Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies (21 October, 2023)

  Nurudeen A Adegoke, Tuba N Gide, Yizhe Mao, Camelia Quek, Ellis Patrick, Matteo S Carlino, Serigne N Lo, Alexander Maxwell Menzies, Ines Pires da Silva, Ismael A Vergara, Georgina Long, Richard A Scolyer, James S Wilmott
• Original research: Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma (19 October, 2023)

  Minjiang Chen, Pengfei Ma, Yongchang Zhang, Dong Wang, Zhuang Yu, Yujie Fu, Xiaojing Zhao, Mengzhao Wang, Guanglei Zhuang, Ying Jing
• Original research: AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors (19 October, 2023)

  Sophia Frentzas, Steven Kao, Rang Gao, Hao Zheng, Ahsan Rizwan, Nageshwar Budha, Luz de la Hoz Pedroza, Wei Tan, Tarek Meniawy
• Original research: Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer (18 October, 2023)

  Abdul Rafeh Naqash, Justin D McCallen, Emma Mi, Sanna Iivanainen, Mona A Marie, Daria Gramenitskaya, James Clark, Jussi Pekka Koivunen, Shravanti Macherla, Sweta Jonnalagadda, Shanker Polsani, Rahim Ali Jiwani, Maida Hafiz, Mahvish Muzaffar, Leonardo Brunetti, Chipman R G Stroud, Paul R Walker, Kun Wang, Youngmin Chung, Eytan Ruppin, Se-Hoon Lee, Li V Yang, David J Pinato, Joo Sang Lee, Alessio Cortellini
• Original research: Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer (18 October, 2023)

  Mehmet Akce, Batoul Farran, Jeffrey M Switchenko, Manali Rupji, Sandra Kang, Lana Khalil, Amanda Ruggieri-Joyce, Brian Olson, Walid L Shaib, Christina Wu, Olatunji B Alese, Maria Diab, Gregory B Lesinski, Bassel F El-Rayes
• Original research: Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (17 October, 2023)

  Philip Clingan, Rahul Ladwa, Daniel Brungs, Dean Laurence Harris, Margaret McGrath, Susan Arnold, Jermaine Coward, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Andrew Mant, Vinay Sharma, Hong Shue, Andrea Tazbirkova, Miguel-Angel Berciano-Guerrero, Chaiyut Charoentum, Stéphane Dalle, Arunee Dechaphunkul, Oleksandr Dudnichenko, Piotr Koralewski, Iwona Lugowska, Henri Montaudié, Eva Muñoz-Couselo, Virote Sriuranpong, James Oliviero, Jayesh Desai
• PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity (4 October, 2023)

  Paul Koller, Natalia Baran, Karine Harutyunyan, Antonio Cavazos, Saradhi Mallampati, Renee L Chin, Zhou Jiang, Xian Sun, Heng-Huan Lee, Jennifer L Hsu, Patrick Williams, Xuelin Huang, Michael A Curran, Mien-Chie Hung, Marina Konopleva